These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15026791)

  • 21. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
    Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
    Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
    Heras P; Kritikos K; Hatzopoulos A; Georgopoulou AP
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):653-6. PubMed ID: 19552728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient management issues in metastatic bone disease.
    Cameron D
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):79-82. PubMed ID: 15490381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
    Rizzoli R
    Ann Oncol; 2004 May; 15(5):700-1. PubMed ID: 15111335
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
    Westermann AM
    Ann Oncol; 2004 Mar; 15(3):537-8. PubMed ID: 14998861
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.